Ac-SDKP vs Chonluten

Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.

Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is an endogenous tetrapeptide generated from the N-terminus of thymosin beta-4 by the enzyme prolyl oligopeptidase, with further regulation by angiotensin-converting enzyme (ACE), and is characterized by roles in hematopoietic progenitor regulation and anti-fibrotic signaling in renal, cardiac, and vascular tissue. Ac-SDKP inhibits collagen synthesis and fibroblast proliferation, reduces TGF-beta-1-mediated fibrotic signaling, and promotes anti-inflammatory macrophage polarization in preclinical models, suggesting a role in tissue homeostasis downstream of the thymosin beta-4 pathway. Preclinical studies in rodent models of renal fibrosis and systemic lupus erythematosus — predominantly from the NIH-funded Rhaleb and Carretero laboratory at Henry Ford Health — have demonstrated that exogenous Ac-SDKP reduces collagen deposition and inflammatory infiltrate; no human clinical trials have been completed or indexed in PubMed. Ac-SDKP has no FDA approval and no approved indication in any jurisdiction; it is studied as a research compound with a plausible anti-fibrotic mechanism and consistent preclinical evidence, but extrapolation of rodent findings to human therapeutic outcomes has not been validated by any clinical investigation.

Tripeptide bioregulator targeting bronchial epithelial cells; normalizes gene expression in bronchial tissue; promotes epithelial regeneration

Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) classified as a Khavinson-class bioregulator peptide targeted at bronchial and lung epithelial tissue, investigated for cytoprotective and anti-aging properties in the respiratory epithelium through proposed gene expression regulatory mechanisms. Like other short Khavinson bioregulator peptides, chonluten is proposed to reach target bronchial cells via proton-coupled oligopeptide transporter (POT) and large amino acid transporter (LAT) uptake mechanisms, and to modulate transcriptional activity in aging or injured lung tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport mechanisms via POT and LAT carriers and demonstrated gene expression regulation by short peptides across multiple tissue types, providing the mechanistic framework within which chonluten's bronchial effects are proposed. Chonluten has no FDA approval or regulatory approval in any major jurisdiction outside Russia; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Chonluten vs cerluten: lung vs bronchial specificity Chonluten is a Khavinson-class short bioregulator peptide proposed to target lung parenchymal tissue rather than the bronchial epithelium (cerluten's proposed target). In the Khavinson organ-specific bioregulator model, different tripeptide or tetrapeptide sequences are proposed to reach distinct tissue types via amino acid transporters and modulate gene expression selectively in those tissues. Chonluten's research applications focus on age-related pulmonary function decline, oxidative stress in lung tissue, and support of alveolar cell function — complementary to but distinct from bronchial applications. Research context for chonluten, like other Khavinson class peptides, comes primarily from the Khavinson Institute (St. Petersburg) preclinical aging models and observational clinical data from Eastern European medical settings; independent large-scale RCT evidence is absent. Standard Khavinson protocol cycles apply: oral capsule, 10–20 day cycles, rest intervals. Chonluten is available from specialty Eastern European suppliers and Russian pharmacy channels; it is not an approved pharmaceutical in Western regulatory jurisdictions. It is sometimes stacked with cerluten in protocols targeting comprehensive respiratory tissue support, though no clinical evidence for this combination exists.